{"id":"bupropion-xl-300","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Insomnia"},{"rate":"17-24%","effect":"Dry mouth"},{"rate":"13-18%","effect":"Nausea"},{"rate":"14-26%","effect":"Headache"},{"rate":"6-11%","effect":"Dizziness"},{"rate":"0.4%","effect":"Seizures"},{"rate":"2-4%","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the reuptake of norepinephrine and dopamine, bupropion increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling. Unlike SSRIs, it does not significantly affect serotonin reuptake. The XL formulation provides extended-release delivery for once-daily dosing, maintaining therapeutic levels throughout the day.","oneSentence":"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:11.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Seasonal affective disorder"},{"name":"Smoking cessation (as adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT04634071","phase":"PHASE2","title":"Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment","status":"COMPLETED","sponsor":"Joseph Valentino, MD","startDate":"2021-01-12","conditions":"Smoking Cessation, Cancer, Treatment-Related","enrollment":126},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT03993457","phase":"PHASE4","title":"Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-07-23","conditions":"Depression","enrollment":18},{"nctId":"NCT03180294","phase":"PHASE2","title":"Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-05-31","conditions":"Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma","enrollment":230},{"nctId":"NCT01077024","phase":"PHASE3","title":"Smoking-Cessation and Stimulant Treatment (S-CAST)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2010-02","conditions":"Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence","enrollment":538},{"nctId":"NCT03169244","phase":"PHASE2","title":"Buproprion for Binge Drinking","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-09-04","conditions":"Alcohol Abuse","enrollment":42},{"nctId":"NCT02209597","phase":"PHASE4","title":"Clinical Study of Generic and Brand Bupropion in Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-06-25","conditions":"Major Depressive Disorder","enrollment":74},{"nctId":"NCT02842073","phase":"PHASE2","title":"An Open Label Trial of Bupropion and Naltrexone for Binge Drinking","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-11-01","conditions":"Binge Drinking","enrollment":12},{"nctId":"NCT00429169","phase":"PHASE4","title":"Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2004-06","conditions":"Depression","enrollment":101},{"nctId":"NCT02698553","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-23","conditions":"Depressive Disorder, Major","enrollment":16},{"nctId":"NCT00404755","phase":"PHASE4","title":"Dichotic Listening as a Predictor of Medication Response in Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2006-07","conditions":"Major Depressive Disorder, Dysthymia","enrollment":17},{"nctId":"NCT00519428","phase":"PHASE4","title":"Does Dual Therapy Hasten Antidepressant Response?","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-08","conditions":"Major Depressive Disorder","enrollment":245},{"nctId":"NCT00439868","phase":"PHASE1","title":"A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-16","conditions":"Depressive Disorder","enrollment":33},{"nctId":"NCT00861939","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-03","conditions":"Depression","enrollment":28},{"nctId":"NCT01046214","phase":"PHASE1","title":"Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions","status":"TERMINATED","sponsor":"Teva Pharmaceuticals USA","startDate":"2010-01","conditions":"Depressive Disorder","enrollment":8},{"nctId":"NCT00296777","phase":"PHASE4","title":"Treatment of Depression Following Multiple Brain Tests","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-12","conditions":"Major Depression, Dysthymia","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Wellbutrin","Par","Mylan","Valeant"],"phase":"marketed","status":"active","brandName":"Bupropion XL 300","genericName":"Bupropion XL 300","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (as adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}